Skip to content
All resources

GLP-1 and metabolic

Eloralintide Phase 2: What the Amylin Agonist Trial Reported

AM

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 9 sections
  1. What is eloralintide?
  2. How amylin agonism differs from GLP-1 agonism
  3. The phase 2 trial: design
  4. The phase 2 trial: what it reported
  5. Tolerability: nausea and fatigue
  6. How eloralintide relates to cagrilintide
  7. What the phase 2 trial cannot answer
  8. What comes next: phase 3
  9. Frequently asked questions

Eloralintide is an investigational, selective amylin receptor agonist developed by Eli Lilly. Its phase 2 trial, published in The Lancet in 2025, randomised 263 adults with obesity or overweight and no diabetes to eloralintide or placebo for 48 weeks. Mean weight change ranged from −9% to −20% across the eloralintide groups, against −0.4% on placebo. Nausea and fatigue were the most common adverse events. It is approved nowhere; phase 3 trials are now recruiting.

A pancreatic islet releasing small hormone molecules, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: an islet, where amylin is made.

What is eloralintide?

Eloralintide (development code LY3841136) is a long-acting synthetic analogue of amylin, a 37-amino-acid hormone that the pancreatic beta cell releases alongside insulin. Amylin slows gastric emptying, suppresses glucagon after a meal and acts in the brainstem on satiety signalling, as reviewed by Hay and colleagues. Native amylin is unstable and short-lived, which is why every drug candidate in this class is an engineered analogue.

The word that sets eloralintide apart is "selective". Amylin receptors are not one protein. They form when the calcitonin receptor pairs with one of three receptor activity-modifying proteins, giving the subtypes AMY1, AMY2 and AMY3, and the calcitonin receptor can also signal on its own. In the discovery paper, Briere and colleagues reported that eloralintide preferentially activated the human AMY1 receptor: about 12-fold more potently than the calcitonin receptor and 11-fold more than AMY3. In lean rats it produced significantly less conditioned taste avoidance, a rodent proxy for nausea, than cagrilintide, which the authors describe as a non-selective amylin receptor agonist.

That rodent comparison is the design hypothesis behind the molecule: that leaning towards one amylin receptor subtype might keep the appetite effect while reducing the nausea. It is a hypothesis about a mechanism, and whether it holds in people is exactly what the clinical trials are for. For background on receptor subtypes and why selectivity matters, see how peptide receptors work.

How amylin agonism differs from GLP-1 agonism

GLP-1 is an incretin, a gut hormone that amplifies insulin release after food and acts centrally on appetite. Semaglutide acts at the GLP-1 receptor, tirzepatide at the GLP-1 and GIP receptors, and retatrutide adds the glucagon receptor. The receptor guide sets these out.

Amylin is not an incretin. It comes from the pancreas rather than the gut, and it works through the calcitonin-receptor family rather than any incretin receptor. The two pathways overlap in what they influence, including food intake, gastric emptying and post-meal glucagon, but not in how they are reached. That is the whole scientific case for studying them together: if two pathways reduce intake by different routes, their effects might add, or a combination might reach the same weight loss with less of each. Neither outcome follows automatically, and combination trials are under way precisely because it cannot be predicted.

The phase 2 trial: design

FeatureDetail
RegistrationNCT06230523 on ClinicalTrials.gov
DesignPhase 2, double-blind, randomised, placebo-controlled
Sites46 research centres in the USA
PopulationAdults aged 18–75 with BMI of 30 or more, or 27 or more with a weight-related condition; type 2 diabetes excluded
Participants263 randomised: 210 to eloralintide, 53 to placebo
ArmsFour fixed-dose groups and two dose-escalation schemes, plus placebo
Duration48 weeks
Primary endpointPercent change in body weight from baseline at week 48
BaselineMean age 49, mean weight 109.1 kg, mean BMI 39.1; 78% female
FundingEli Lilly

The population matters for reading the result. Nearly four in five participants were women, the mean BMI was well into class II obesity, and people with diabetes were excluded. Weight loss in incretin-drug trials has generally been smaller in people with type 2 diabetes, so these results cannot be carried over to that group.

The phase 2 trial: what it reported

Using the efficacy estimand, which estimates the effect had participants stayed on treatment, mean percent change in body weight at 48 weeks was −9%, −12%, −18% and −20% across the four fixed-dose groups in ascending order, and −20% and −16% in the two escalation groups. Placebo was −0.4%. Every eloralintide arm's confidence interval sat clear of placebo's.

Three features of the result deserve attention.

The curve flattens at the top. The two highest exposures both landed at about −20%. That could be a genuine plateau in the dose-response, or simply what 48 weeks allows. The abstract does not say whether weight was still falling at week 48.

The efficacy estimand flatters. It answers "what if everyone stayed on the drug?" A treatment-regimen estimand, which counts everyone randomised regardless of discontinuation, is the more conservative number and typically smaller. The study design guide explains why the two diverge.

The arms were small. Individual groups ranged from 24 to 54 participants. That is normal for dose-finding, but it means confidence intervals several percentage points wide and very limited power to detect uncommon adverse events.

Tolerability: nausea and fatigue

The most common adverse events were nausea and fatigue, and neither tracked dose neatly.

Arm (ascending exposure)NauseaFatigue
Placebo14%12%
Lowest fixed dose11%0%
Second fixed dose13%13%
Third fixed dose64%29%
Highest fixed dose33%43%
Escalation to highest, from the third dose54%46%
Escalation to highest, from the second dose25%21%

Nausea did not rise steadily with exposure. It peaked at 64% in the third fixed-dose arm, fell to 33% in the highest fixed-dose arm, and was lowest among the high-exposure arms (25%) in the escalation scheme that stepped up most gradually. With arms of 24 to 54 people, some of that unevenness may be chance, and the abstract does not explain it. Fatigue behaved differently: it rose with exposure and reached 43–46% in the highest-exposure arms. That is a notable rate for a class promoted partly on tolerability, and the abstract does not describe its severity or duration.

The earlier phase 1 multiple-ascending-dose study (100 participants, 12 weeks) reported decreased appetite (19%), headache (12%) and fatigue (11%) as the most common events, with nausea in 8% and vomiting in 4%. Those were short exposures without escalation in a smaller, mostly male group, so the low gastrointestinal rates there do not predict the 48-week picture.

How eloralintide relates to cagrilintide

Cagrilintide is Novo Nordisk's long-acting amylin analogue and the class's reference point. It has a phase 2 dose-finding trial of its own, published by Lau and colleagues in 2021, and has been studied mostly in combination with semaglutide as CagriSema. The two molecules are not interchangeable. Cagrilintide engages amylin and calcitonin receptors broadly, while eloralintide was engineered for AMY1 preference. The claim that this yields better tolerability rests so far on rodent taste-avoidance data and cross-trial impressions. No trial has compared the two directly, and setting a percentage from one trial beside a percentage from the other mixes populations, durations and estimands. The three-way comparison of tirzepatide, eloralintide and mazdutide covers the same trap for cross-class comparisons.

What the phase 2 trial cannot answer

  • Durability. Forty-eight weeks does not show where weight settles, or what happens after treatment stops.
  • Body composition. The abstract reports total weight only. Rodent data suggested mostly fat-mass loss, but that has not been shown in the human trial.
  • Rare harms. A total of 210 people on active drug cannot detect events that occur in one in a thousand.
  • Clinical outcomes. No cardiovascular, renal or mortality data exist.
  • Combinations. Adding eloralintide's effect to tirzepatide's by arithmetic is not evidence. Only randomised combination trials can answer that.

What comes next: phase 3

ClinicalTrials.gov lists a phase 3 programme named ENLIGHTEN. It includes trials in obesity without diabetes (NCT07321886), obesity with type 2 diabetes (NCT07282600), obstructive sleep apnea (NCT07369011), knee osteoarthritis pain (NCT07353931), and people with persistent obesity already receiving an incretin drug (NCT07392190). Separate phase 3 trials named AMPLIFY, listed as not yet recruiting, will compare eloralintide combined with tirzepatide against each drug alone and placebo (NCT07881432). Until those report, the phase 2 trial is the main human efficacy evidence. For how sleep apnea trials are measured, see the tirzepatide and sleep apnea article.

Frequently asked questions

How much weight loss did eloralintide produce in phase 2? Mean change at 48 weeks ranged from −9% to −20% across the six eloralintide arms, against −0.4% on placebo, using an estimand that assumes participants stayed on treatment. The trial enrolled 263 adults without diabetes, 78% of them women. Results from this population cannot be assumed to apply to people with type 2 diabetes.

Is eloralintide approved anywhere? No. Eloralintide is an investigational compound in Eli Lilly's development programme, and no regulator has authorised it for any use. Phase 3 trials in obesity, type 2 diabetes, sleep apnea and knee osteoarthritis are recruiting. A completed phase 2 trial is evidence for designing phase 3, not an authorisation.

How is eloralintide different from a GLP-1 drug? It acts on amylin receptors, which belong to the calcitonin-receptor family, rather than on the GLP-1 receptor. Amylin is a pancreatic hormone released with insulin, not a gut incretin. Both pathways influence food intake and gastric emptying, which is why combination trials exist, but they reach those effects by different receptors.

Is eloralintide better tolerated than cagrilintide? That has not been shown. Eloralintide was designed for amylin-receptor selectivity, and in rats it caused less taste avoidance than cagrilintide. In people, nausea in phase 2 reached 64% in one arm and fatigue up to 46%. No trial has compared the two molecules directly in humans.

When will phase 3 results be available? ClinicalTrials.gov lists the ENLIGHTEN phase 3 trials as recruiting and the AMPLIFY combination trials as not yet recruiting, so no phase 3 efficacy data exist yet. Registry entries record planned endpoints and completion dates, which change. Check the registry numbers above for current status rather than relying on a projected date.

Selected Research References

  1. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631-2643. pubmed.ncbi.nlm.nih.gov/41207310
  2. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. pubmed.ncbi.nlm.nih.gov/41109426
  3. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026;28:2651-2660. pubmed.ncbi.nlm.nih.gov/41559929
  4. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews. 2015;67(3):564-600. pubmed.ncbi.nlm.nih.gov/26071095
  5. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398:2160-2172. pubmed.ncbi.nlm.nih.gov/34798060

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.